|
Oct 11
|
ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential
|
|
Oct 9
|
Wall Street Analysts Predict a 42.98% Upside in ANI (ANIP): Here's What You Should Know
|
|
Jun 24
|
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal
|
|
Jun 24
|
Alimera Sciences shares jump by 77% after being acquired by ANI
|
|
Jun 24
|
ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences
|
|
Jun 23
|
ANI Pharmaceuticals (NASDAQ:ANIP) shareholders are still up 77% over 3 years despite pulling back 6.5% in the past week
|
|
Jun 21
|
Strength Seen in Gilead (GILD): Can Its 8.5% Jump Turn into More Strength?
|
|
Feb 20
|
ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
|
|
Dec 7
|
Investing in ANI Pharmaceuticals (NASDAQ:ANIP) three years ago would have delivered you a 59% gain
|
|
Oct 6
|
ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: Here's Why
|
|
Oct 5
|
(ANIP) Advances While Market Declines: Some Information for Investors
|
|
Oct 2
|
ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares
|
|
Aug 11
|
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
|
|
Aug 10
|
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
|
|
Aug 9
|
ANI (ANIP) Reports Q2 Earnings: What Key Metrics Have to Say
|
|
Aug 9
|
ANI Pharmaceuticals (ANIP) Beats Q2 Earnings and Revenue Estimates
|
|
Aug 9
|
ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
|
|
Jul 11
|
ANI Pharmaceuticals (ANIP) Gains But Lags Market: What You Should Know
|